New data positions Astellas prostate cancer med Xtandi to grab market share from J&J’s Zytiga

Tracy Staton

Some new on the drug promises to heat up competition with Johnson & Johnson's . Medivation and its partner Pharma unveiled final data a late-stage trial showing that Xtandi prolonged patients' lives and delayed tumor growth when used before chemotherapy.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS